2 June 2026 - AbbVie today announced that the European Commission has approved Aquipta (atogepant) for the acute treatment of migraine in adults with or without aura, to be taken as needed. 

This approval is the second indication in the European Union for Aquipta, an oral calcitonin gene-related peptide receptor antagonist (gepant), which is now approved as both an acute treatment option for migraine attacks in adults and as a once-daily preventive treatment option for adults with chronic or episodic migraine who experience four or more migraine days per month.

Read AbbVie press release